This round is no longer accepting investments, but hundreds just like it are live now.

Log In


Virtual care for respiratory illnesses

Keva Health has developed a SaaS platform to provide remote monitoring of respiratory illnesses at home. Our mission is to help the tens of millions of adults and children suffering from chronic respiratory illnesses improve their quality of life with our suite of digital health products, including our patient app, Bluetooth-powered devices, physician platform, and nursing services. Our award-winning product is already in-market and we believe we are ready to scale. KevaHealth is in the revenue stage of development.

This Reg CF offering is made available through StartEngine Capital, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.

$23,714.76 Raised


Our technology aims to prevent ER visits for patients and reduce the physician burden through a Bluetooth-connected device for highly accurate home monitoring of symptoms along with an app that transfers valuable data to doctors and nurses.

The Remote Patient Monitoring market has experienced explosive growth since the pandemic, predicted to expand from $53.6 billion to $175.2 billion by 2027 at a CAGR of 26.7%.**

Our highly qualified team and innovative product has won a CTIA Wireless Foundation Award, and we were featured in the Babson U.S. Annual GEM Report.***

*Information from Science Direct & The National Library of Medicine (Source | Source)

**Information from Report Linker (Source)

***Information from the Global Entrepreneurship Monitor (GEM) 2021/2022 U.S. Report (Source)


Empowering Patients with At-Home Respiratory Monitoring

Keva Health is seeking to close healthcare gaps in chronic care management by engaging patients in their own medical condition. As our founders treated their daughter’s asthma, they found many limitations in the transition from episodic monitoring in a doctor’s care, to continuous monitoring at home in between visits. We designed our Respiratory Remote Patient Monitoring Platform to provide 24/7 at-home care, improving patient quality of life while simultaneously reducing the healthcare economic burden. 

The Problem & Our solution

Improving Outcomes and Lowering Costs

The costs related to acute exacerbation of COPD are estimated to be approximately $4069/year per patient, increasing the frequency and severity of symptoms (Source). Meanwhile, Asthma affects over 20 million Americans– essentially 1 in 13 people (Source). The costs of treating and monitoring these diseases are increasing, without significant advances in the quality of care.


Our Bluetooth-connected devices, user-friendly app, and physician platform track key patient vitals including lung function. Our unique patent pending engine allows us to use patients' history and published guidelines on the standard of care to provide guidance and nudges thereby improving outcomes. By providing automated guidance and escalation management we allow the physicians to focus on the patients that need the most attention. Access to data from devices and the patient's history outside of the office enables physicians to make better decisions. We charge a per-patient fee to the physician for providing the Keva Health program to their patients.


the market & Our Traction

Award-Winning Innovation in the
Fast-Growing Telehealth Space

The Remote Patient Monitoring market is quickly expanding, projected to grow from $53.6 billion to $175.2 billion by 2027, at a Compounded Annual Growth Rate (CAGR) of 26.7% (Source). This growth has increased tremendously since the Covid-19 pandemic heightened demand for telehealth options. Now, nearly 76% of hospitals in the U.S. offer some form of virtual care for their patients (Source). 

*The above testimonials may not be representative of the opinions of other medical experts or the experiences of other customers and is not a guarantee of future performance or success.

*The above testimonials may not be representative of the opinions of other medical experts or the experiences of other customers and is not a guarantee of future performance or success.

Recently, we signed a major new partnership with a digital formulary platform company and presented our results at the CHEST Conference. We have earned several awards for our technology, including the Silver Award for Business Excellence, the Connect Tech Innovation Challenge Award, and a grant from Mass Tech Innovation. We were also a finalist for the CTIA Wireless Foundation Award. We currently have a patent pending, protecting our systems and methods to monitor and manager respiratory diseases using a combination of the app, our device, and our unique platform. This patent can eventually be expanded to any chronic disease.

Why Invest

Bringing Respiratory Care to All Patients


With award-winning technology and exciting new partnerships, we believe we are ready to get our product in the hands of as many patients as possible. We plan to further develop our technology, build a robust marketing and sales team to further scale up our product, and establish its presence in the chronic respiratory disease market. Join us, as we improve the quality of life for people suffering from chronic respiratory illnesses by providing quality at-home symptom monitoring to patients everywhere.


251 Little Falls Dr.
Wilmington, DE 19808

Keva Health has developed a SaaS platform to provide remote monitoring of respiratory illnesses at home. Our mission is to help the tens of millions of adults and children suffering from chronic respiratory illnesses improve their quality of life with our suite of digital health products, including our patient app, Bluetooth-powered devices, physician platform, and nursing services. Our award-winning product is already in-market and we believe we are ready to scale. KevaHealth is in the revenue stage of development.


Jyotsna Mehta
Jyotsna Mehta
CEO & Co-Founder

A dynamic and accomplished professional bringing over twenty years of combined experience in academia, regulatory affairs and pharmaceutical industry working in both global and US roles spanning multiple therapeutic areas with a strong foundation in pharmaceutical sciences, digital health, real-world evidence, epidemiology, health outcomes, and pharmacoeconomics. She founded Keva Health which aspires to be a leader in remote care for respiratory illness. Its proprietary platform is integrating innovative remote monitoring functionality with evidence-based self-monitoring programs for patients with chronic respiratory diseases to improve outcomes and reduce costs.

Shail Mehta
Shail Mehta
Chief Technical officer & Co-founder

Product & Engineering leader responsible for leading the engineering team with experience in delivering secure, reliable, and resilient platforms and solutions. Oversees both the internal infrastructure and administration as well as production operations.

Shail has experience working with startups and large organizations, with the proven ability to produce revenue-generating products. He has worked with hosted and SaaS solutions to create product experiences that delight end users.

Shail works 10 hours a week on KevaHealth.

Dr. Ramin Rafie, MD

Dr. Ramin Rafie, MD

Clinical Advisor

Dr.Ramin is a primary care physician and an in-house expert for hospital at home model of care and ACO model. He serves as hospice director at Elara Caring and is an Executive Advisory Council Member at Angel MD. He is currently bringing connections and helping with fundraising.

Ramin works 1-2 hours a week on KevaHealth

Dr. Varada Divgi

Dr. Varada Divgi

Director, Pediatric Pulmonary Program

With years of experience in pediatric pulmonology, Dr. Divgi plays an essential role with her 40 years of experience with asthma & Chronic Lung Disease patients. Dr. Divgi is the foundation of the Keva teams’ knowledge base within the chronic respiratory space. 

Dr. Varada Divgi works 2-4 hours a week on KevaHealth.

Gustavo Bottan

Gustavo Bottan

Advisor, Partnerships

Gustavo leads the partnerships for the company such as building network with non profit organizations, advocacy and international market exploration.

Gustavo works 0.5 hours a week on KevaHealth.

Priya Anand

Priya Anand

Director, Marketing

Priya plays an essential role in the development of company resources and advertising efforts. She leads Keva’s marketing efforts to build brand awareness and sales initiatives.  

Dr. Philip Silkoff

Dr. Philip Silkoff

Clinical Advisor

Dr. Phillip Silkoff is currently helping with connections and partnerships. He is experienced with pharmaceutical industry , drug and device development and has several patents in his work in the pulmonary field. 

Phillip works 1 hour a week on KevaHealth.

Dr. Dhrumil Shah

Dr. Dhrumil Shah

Clinical Advisor

Dr.Shah is CMIO at Compass Medical and serves as strategic advisor for KevaHealth. He is a strong believer and thought leader in advanced digital health, value based care and mentors various digital startup entrepreneurs.  

Dr. Shah works 1-2 hours a week on KevaHealth.

Dr. Paul Helmuth

Dr. Paul Helmuth

Clinical Advisor

Dr. Helmuth served as a consultant and in an advisory capacity. With more than 25 years experience as a primary care physician, PJ served as Medical Director of Quality & Population Health for the largest healthcare organization in western Massachusetts and has interests and expertise in clinical quality, value-based care, and virtual care.  

Dr. Helmuth works 1 hour a week on KevaHealth.

Vijay Bhatt

Vijay Bhatt


Dr. Bhatt is Deputy CTO at Harvard Pilgrim HealthCare and has been a mentor and advisor to Keva team since they joined the Tie Scaleup Program. He excels in guiding on both technology and payor strategy for Keva’s team. 

Vijay works 1 hour a week on KevaHealth.


Jun 2, 2023
$10k - $1.23M
Common Stock
Common Stock

Maximum Number of Shares Offered subject to adjustment for bonus shares

Most Recent Fiscal Year-End

Prior Fiscal Year-End

Total Assets



Cash & Cash Equivalents



Accounts Receivable



Short-Term Debt



Long-Term Debt



Revenue & Sales



Costs of Goods Sold



Taxes Paid



Net Income



*Maximum number of shares offered subject to adjustment for bonus shares. See Bonus info below.

Voting Rights of Securities Sold in this Offering

Voting Proxy. Each Subscriber shall appoint the Chief Executive Officer of the Company (the “CEO”), or his or her successor, as the Subscriber’s true and lawful proxy and attorney, with the power to act alone and with full power of substitution, to, consistent with this instrument and on behalf of the Subscriber, (i) vote all Securities, (ii) give and receive notices and communications, (iii) execute any instrument or document that the CEO determines is necessary or appropriate in the exercise of its authority under this instrument, and (iv) take all actions necessary or appropriate in the judgment of the CEO for the accomplishment of the foregoing. The proxy and power granted by the Subscriber pursuant to this Section are coupled with an interest. Such proxy and power will be irrevocable. The proxy and power, so long as the Subscriber is an individual, will survive the death, incompetency and disability of the Subscriber and, so long as the Subscriber is an entity, will survive the merger or reorganization of the Subscriber or any other entity holding the Securities. However, the Proxy will terminate upon the closing of a firm-commitment underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933 covering the offer and sale of Common Stock or the effectiveness of a registration statement under the Securities Exchange Act of 1934 covering the Common Stock.

Investment Incentives & Bonuses*


Friends and Family Early Birds

Invest within the 72 hours and receive 20% bonus shares.

Super Early Bird Bonus

Invest within the first week and receive 15% bonus shares.

Early Bird Bonus

Invest within the first three weeks and receive 10% bonus shares.



Invest $450+ and receive 2% Bonus Shares.


Invest $1,000 + and receive 5% Bonus Shares.

$4,500 +

Invest $4,500+ and receive 10 % Bonus Shares.


Invest $15,000+ and receive 15% Bonus Shares.


Invest $20,000+ and receive 20% Bonus Shares + Private zoom call with Chief Executive and/or Chief Technology Officer.  

*In order to receive perks from an investment, one must submit a single investment in the same offering that meets the minimum perk requirement. Bonus shares from perks will not be granted if an investor submits multiple investments that, when combined, meet the perk requirement. All perks occur when the offering is completed.

The 10% StartEngine Owners’ Bonus

KevaHealth Inc. will offer 10% additional bonus shares for all investments that are committed by investors that are eligible for the StartEngine Crowdfunding Inc. Owner’s bonus.

This means eligible StartEngine shareholders will receive a 10% bonus for any shares they purchase in this offering. For example, if you buy 100 shares of Common Stock at $1.22 per share, you will receive 110 Common Stock, meaning you’ll own 110 shares for $122. Fractional shares will not be distributed and share bonuses will be determined by rounding down to the nearest whole share.

This 10% Bonus is only valid during the investor eligibility period. Investors eligible for this bonus will also have priority if they are on a waitlist to invest and the company surpasses its maximum funding goal. They will have the first opportunity to invest should room in the offering become available if prior investments are canceled or fail.

Investors will receive the highest single bonus they are eligible for among the bonuses based on the amount invested and time of offering elapsed (if any). Eligible investors will also receive the Owner’s Bonus in addition to the aforementioned bonus.

Irregular Use of Proceeds

The Company might incur Irregular Use of Proceeds that may include but are not limited to the following over $10,000: Vendor payments.


Owners bonus
Stack Owner's Bonus & Rewards!

Members get an extra 10% shares in addition to rewards below!


Multiple investments in an offering cannot be combined to qualify for a larger campaign perk. Get rewarded for investing more into KevaHealth.



Adam Sampson

6 months ago

How does your company compare/differ from VitalFlo



Kendall R. Pagone

7 months ago

I might have miss it, but how much does the average person/ family pay for your services per visit, month, or year?




Cancel anytime before 48 hours before a rolling close or the offering end date.



We want you to succeed and get the most out of your money by offering rewards and memberships!


Your info is your info. We take pride in keeping it that way!


Invest in over 200 start-ups and collectibles!

With Regulation A+, a non-accredited investor can only invest a maximum of 10% of their annual income or 10% of their net worth per year, whichever is greater. There are no restrictions for accredited investors.

With Regulation Crowdfunding, non-accredited investors with an annual income or net worth less than $124,000, are limited to invest a maximum of 5% of the greater of those two amounts. For those with an annual income and net worth greater than $124,000, he/she is limited to investing 10% of the greater of the two amounts.

At the close of an offering, all investors whose funds have “cleared” by this time will be included in the disbursement. At this time, each investor will receive an email from StartEngine with their Countersigned Subscription Agreement, which will serve as their proof of purchase moving forward.

Please keep in mind that a company can conduct a series of “closes” or withdrawals of funds throughout the duration of the campaign. If you are included in that withdrawal period, you will be emailed your countersigned subscription agreement and proof of purchase immediately following that withdrawal.

StartEngine assists companies in raising capital, and once the offering is closed, we are no longer involved with whether the company chooses to list shares on a secondary market, or what occurs thereafter. Therefore, StartEngine has no control or insight into your investment after the close of the live offering. In addition, we are not permitted to provide financial advice. You may want to contact a financial professional to discuss possible investment outcomes.

For Regulation Crowdfunding, investors are able to cancel their investment at any point throughout the campaign up until 48 hours before the closing of the offering. Note: If the company does a rolling close, they will post an update to their current investors, giving them the opportunity to cancel during this timeframe. If you do not cancel within this 5-day timeframe, your funds will be invested in the company, and you will no longer be able to cancel the investment. If your funds show as ‘Invested’ on your account dashboard, your investment can no longer be canceled.

For Regulation A+, StartEngine allows for a four-hour cancelation period. Once the four-hour window has passed, it is up to each company to set their own cancelation policy. You may find the company’s cancelation policy in the company’s offering circular.

Once your investment is canceled, there is a 10-day clearing period (from the date your investment was submitted). After your funds have cleared the bank, you will receive your refund within 10 business days.

Refunds that are made through ACH payments can take up to 10 business days to clear. Unfortunately, we are at the mercy of the bank, but we will do everything we can to get you your refund as soon as possible. However, every investment needs to go through the clearing process in order to get sent back to the account associated with the investment.

Both Title III (Regulation Crowdfunding) and Title IV (Reg A+) help entrepreneurs crowdfund capital investments from unaccredited and accredited investors. The differences between these regulations are related to the investor limitations, the differing amounts of money companies are permitted to raise, and differing disclosure and filing requirements. To learn more about Regulation Crowdfunding, click here, and for Regulation A+, click here.


Get To Know Us

Our Team



Important Message

Unless indicated otherwise with respect to a particular issuer, all securities-related activity is conducted by regulated affiliates of StartEngine: StartEngine Capital, LLC, a funding portal registered here with the US Securities and Exchange Commission (SEC) and here as a member of the Financial Industry Regulatory Authority (FINRA), or StartEngine Primary, LLC, a broker-dealer registered with the SEC and FINRASIPC . You can review the background of our broker-dealer and our investment professionals on FINRA’s BrokerCheck here. StartEngine Secondary is an alternative trading system regulated by the SEC and operated by StartEngine Primary, LLC, a broker dealer registered with the SEC and FINRA. StartEngine Primary, LLC is a member of SIPC and explanatory brochures are available upon request by contacting SIPC at (202) 371-8300.

Investment opportunities posted and accessible through the site are of three types:

1) Regulation A offerings (JOBS Act Title IV; known as Regulation A+), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Primary, LLC (unless otherwise indicated). 2) Regulation D offerings (Rule 506(c)), which are offered only to accredited investors. These offerings are made through StartEngine Primary, LLC. 3) Regulation Crowdfunding offerings (JOBS Act Title III), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Capital, LLC. Some of these offerings are open to the general public, however there are important differences and risks.

Any securities offered on this website have not been recommended or approved by any federal or state securities commission or regulatory authority. StartEngine and its affiliates do not provide any investment advice or recommendation and do not provide any legal or tax advice with respect to any securities. All securities listed on this site are being offered by, and all information included on this site is the responsibility of, the applicable issuer of such securities. StartEngine does not verify the adequacy, accuracy or completeness of any information. Neither StartEngine nor any of its officers, directors, agents and employees makes any warranty, express or implied, of any kind whatsoever related to the adequacy, accuracy, or completeness of any information on this site or the use of information on this site. See additional general disclosures here.
By accessing this site and any pages on this site, you agree to be bound by our Terms of use and Privacy Policy, as may be amended from time to time without notice or liability.

Canadian Investors Investment opportunities posted and accessible through the site will not be offered to Canadian resident investors. Potential investors are strongly advised to consult their legal, tax and financial advisors before investing. The securities offered on this site are not offered in jurisdictions where public solicitation for offerings is not permitted; it is solely your responsibility to comply with the laws and regulations of your country of residence.

California Investors Only – Do Not Sell My Personal Information

(800-317-2200). StartEngine does not sell personal information. For all customer inquiries, please write to

StartEngine’s Reg A+ offering is made available through StartEngine Crowdfunding, Inc. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. For more information about this offering, please view StartEngine’s offering circular and risk associated with this offering.

StartEngine Marketplace

The availability of company information does not indicate that the company has endorsed, supports, or otherwise participates with StartEngine.

None of the information displayed on or downloadable from (the 'Website') represents a recommendation, offer, or solicitation of an offer to buy or sell any security. It also does not constitute an offer to provide investment advice or service. StartEngine does not (1) make any recommendations or otherwise advise on the merits or advisability of a particular investment or transaction, or (2) assist in the determination of fair value of any security or investment, or (3) provide legal, tax, or transactional advisory services.

All investment opportunities are based on indicated interest from sellers and will need to be confirmed.

Investing in private company securities is not suitable for all investors. An investment in private company securities is highly speculative and involves a high degree of risk. It should only be considered a long-term investment. You must be prepared to withstand a total loss of your investment. Private company securities are also highly illiquid, and there is no guarantee that a market will develop for such securities. Each investment also carries its own specific risks, and you should complete your own independent due diligence regarding the investment. This includes obtaining additional information about the company, opinions, financial projections, and legal or other investment advice. Accordingly, investing in private company securities is appropriate only for those investors who can tolerate a high degree of risk and do not require a liquid investment.

StartEngine Marketplace (“SE Marketplace”) is a website operated by StartEngine Primary, LLC (“SE Primary”), a broker-dealer that is registered with the SEC and a member of FINRA and the SIPC. StartEngine Bulletin Board ("SE BB") is a bulletin board platform that advertises interest in shares of private companies that previously executed Reg CF or Reg A offerings. SE BB enables shareholders to communicate interest in potential sales of shares in private companies and investors to discover, review, and potentially invest in private companies. As a bulletin board platform, SE BB provides a venue for investors to access information about private company offerings and connect with potential sellers. SE BB is distinct and separate from StartEngine Secondary (“SE Secondary”), which is an SEC-registered Alternative Trading System (ATS) operated by SE Primary. SE Secondary facilitates the trading of securities by matching orders between buyers and sellers and facilitating executions of trades on the platform. While a security may be displayed on the bulletin board, these securities will be subject to certain restrictions which may prevent the ability to buy and sell these securities in a timely manner, if at all. Even if a security is qualified to be displayed on the bulletin board, there is no guarantee an active trading market for the securities will ever develop, or if developed, be maintained. You should assume that you may not be able to liquidate your investment for some time or be able to pledge these shares as collateral.